Target intelligence / Profile preview

Mycobacterial F1Fo-ATP synthase (F1Fo-ATP synthase)

Target
F1Fo-ATP synthase
Molecular classification
Enzyme, Molecular motor, Membrane protein complex
01

Overview

The mycobacterial F1Fo-ATP synthase is a large, membrane-embedded enzyme complex essential for ATP production in Mycobacterium species, including Mycobacterium tuberculosis[1][5][3]. It is composed of a soluble F1 sector (subunits α3:β3:γ:δ:ε) responsible for ATP synthesis and a membrane-embedded Fo sector (subunits a:b:b':c9) that forms a rotary motor powered by the proton-motive force[2][4][7]. Unique structural adaptations in mycobacteria include an extended δ subunit and mycobacterium-specific features of the γ and α subunits, which are involved in regulation and species-selective inhibition[3][5]. The enzyme is indispensable for both actively replicating and dormant mycobacteria, making it an attractive therapeutic target[3]. Bedaquiline and related drugs specifically bind the c-ring of the Fo rotor, blocking proton translocation and ATP synthesis, which leads to bacterial death but is generally selective for the mycobacterial enzyme due to differences in binding site structure[1][8]. The essential function and unique mycobacterial elements provide opportunities for selective drug discovery against tuberculosis and related infections[3][5].

Other names
F-ATP synthaseMycobacterial ATP synthaseATP synthaseFoF1-ATPase
02

Mechanism of action

Direct inhibition of proton translocation and ATP synthesis by binding to the c-ring of the Fo rotor, preventing rotation and ion flow, thus collapsing ATP generation and leading to mycobacterial death[1][3][8].

03

Biological functions

ATP synthesis/energy metabolismProton transportMaintenance of proton motive force (pmf)
04

Disease associations

Infection (notably tuberculosis)
05

Safety considerations

Potential for mitochondrial toxicity (since human mitochondrial ATP synthase is homologous, but bedaquiline is highly selective for mycobacterial enzyme)Cardiac/cardiotoxic effects (QT prolongation), but these are related to the drug, not the targetResistance development in Mycobacterium tuberculosis[3][8]
06

Interacting drugs

Bedaquiline (Sirturo)

1 more in the full profile.

07

Biomarkers

No established clinical biomarkers specifically for this target; efficacy is tracked largely by microbiological or clinical response in tuberculosis therapy[3].

Beyond the preview

Go deeper on Mycobacterial F1Fo-ATP synthase (F1Fo-ATP synthase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacterial F1Fo-ATP synthase (F1Fo-ATP synthase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call